NASDAQ$AHCO

AdaptHealth Corp. · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Announced first quarter 2020 financial results, demonstrating resilience amidst COVID-19 challenges and successful deployment of a scalable growth model focused on organic sales, acquisitions, margin expansion, and cash generation.

AdaptHealth Corp. reported a strong first quarter despite COVID-19 challenges, driven by the team's hard work and the company's scalable growth model. The HME business performed well, and two accretive HME business acquisitions were closed and fully integrated. PCS generated $33.9 million in net revenue, with progress made in addressing issues and growth expected in continuous glucose monitoring.

  • Strong first quarter performance reflects the extraordinary hard work, resilience and dedication of the AdaptHealth team.
  • Successfully deploying a scalable growth model focused on organic sales, acquisitions, accretive capital deployment, margin expansion, and cash generation.
  • Closed and fully integrated two significant and accretive HME business acquisitions during the quarter that are also expected to add an aggregate $91 million in net revenue in 2020.
  • Patient Care Solutions (PCS) generated net revenue of $33.9 million for the quarter and exceeded internal revenue and operational projections.

Headline financials

Total Revenue

$191M

Previous: $119M+60.2%
EPS (adj)

-$0.00

Previous: $0.03-114.2%
Capital Expenditures

-$7.53M

No prior period
Free Cash Flow

-$7.69M

No prior period
Net Income

-$158K

Previous: $826K-119.2%
Operating Income

$9.31M

Previous: -$341K+2827.5%
Gross Profit

$24.9M

Previous: $21.8M+14.3%
Cash & Equivalents

$48.2M

No prior period
Total Assets

$662M

No prior period
Stock-Based Comp

$2.22M

No prior period

Revenue & EPS history

AdaptHealth · Revenue · Quarterly

$191M

Q1 2020+60.2%vs Q1 2019
Beat estimate in 4 of 9 quarters(44%)
ActualEstimate

Forward guidance

Based on current trends, the company is affirming its financial guidance for 2020 of net revenue between $790 million to $808 million, Adjusted EBITDA of $160 million to $164 million, and Adjusted EBITDA less Patient Equipment Capex of $98 million to $101 million. This outlook excludes anticipated first year PCS operating losses as well as severance and restructuring costs associated with the PCS acquisition totaling approximately $15 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+0.6%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+1.6%

Avg return

30 days after

52%

16 / 31 earnings

Positive

+34.6%

Q4 2023

Best reaction

-27.9%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-10.0%-13.4%-25.6%
Q4 2025-14.2%-11.1%+10.9%
Q3 2025+17.2%+4.5%+3.2%
Q1 2025+1.7%-1.4%+3.7%
Q4 2024+24.4%+33.1%+24.4%
Q3 2024+0.3%-0.6%-4.2%
Q2 2024-17.2%-14.1%+4.6%
Q1 2024-8.6%-8.8%+4.9%
Q4 2023+34.6%+37.9%+50.9%
Q3 2023-23.1%-18.6%-5.6%
Q2 2023+11.1%+4.4%-19.8%
Q1 2023-8.4%-12.2%-13.8%
Q4 2022-27.9%-27.9%-40.6%
Q3 2022-1.6%+8.4%+4.5%
Q2 2022-8.9%-8.2%-25.7%
Q1 2022+23.7%+42.2%+53.6%
Q4 2021+4.1%+2.3%+2.8%
Q3 2021-5.4%-7.2%-24.1%
Q2 2021+16.4%+13.4%+12.3%
Q1 2021-8.5%-14.9%-10.4%
Q4 2020+2.1%+12.4%+21.7%
Q3 2020+2.6%+0.6%+19.5%
Q2 2020+13.9%+18.0%+7.0%
Q1 2020+1.6%+5.8%+5.5%
Q4 2019+1.8%+1.4%-7.7%
Q3 2019-4.1%-4.9%-3.3%
Q2 2019+0.0%+0.0%-0.6%
Q1 2019+0.0%+0.0%+0.3%
Q4 2018+0.6%+0.7%+1.3%
Q3 2018+0.3%+0.1%+0.4%
Q2 2018+0.0%+0.3%+0.1%
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro